Promoted therapies for hyperkalemia in chronic kidney disease patients in the clinic, dialysis, and hospital setting, and to reduce the risk of eGFR decline. • Attained Q2 NRx goal of 163.54%; Q3 NRx goal of 170%; #1 in District in Trialist conversions. • Increased 32.3% in NRx and 40.2% in TRx. • Recognized 52.9% increase in Hospital DDD units, with 119% DDD volume goal attainment for Q3.• Improved territory performance from #42/119 in Q2 to #13/119 in Q3.

Promoted Rayaldee for chronic kidney disease patients with secondary hyperparathyroidism to targeted nephrologists.• Utilized specialty pharmacies and OPKO Connect reimbursement hub on prescription fulfillment of a specialty therapy, demonstrating consistent prescription growth and addition of new prescribers.• Improved territory ranking from #51/ 63 in Q1 2019 to #8/63 in Q4 2020 for NBRx, #2 in nation on goal attainment.• Analyzed weekly sales reports to develop a key target list, which resulted in NBRx growth and new writers.

Promoted Doptelet in its first-year thrombocytopenia in patients with chronic liver disease scheduled for a surgical procedure. Customer base included hematologists, surgeons and selected primary care. • Utilized specialty pharmacies and Doptelet Connect reimbursement hub on prescription fulfillment of a specialty therapy.

Promoted Symproic in its launch year for opiate-induced constipation to targeted gastroenterology, pain management, and primary care targets on a Shionogi contract. • Recognized as Top third of sales force for achieving 2Q 2018 ranking of 7 of 30 territories calling on gastroenterology.• Positively engaged customers based on segment to establish and maintain value-based relationships.

Promoted Zurampic and Duzallo for the Ironwood Gout Franchise market to targeted primary care, rheumatology and nephrology targets. Promoted Linzess for chronic constipation and Viberzi for irritable bowel syndrome with diarrhea.• Developed comprehensive business plans and identified provider targets to enhance call frequency on high potential office to change provider behavior. Consistently exceeded reach goals in territory. • Drove growth across the franchise, increasing the number of Zurampic/Duzallo prescribers. • Focused on total office call and pharmacy pull-through of scripts.

Promoted Movantik in its launch year for opioid-induced constipation to targeted providers in primary care, and gastroenterology. • Developed business plans and identified provider targets to enhance call frequency to achieve desired conversion of providers to trialists for Movantik.• Initially placed in an underperforming territory, achieved 2Q 2016 ranking of 55 of 280 territories (Top 20%).

Managed vaccine promotion and sales to pediatricians, primary care physicians, and hospitals. Primary promotional responsibility of Gardasil HPV vaccine, Zostavax zoster vaccine, Maxalt for migraine relief, and Januvia for Type II diabetes control promotion. Sucessfully launched Gardasil and Zostavax to targeted primary care and pediatric customers. Managed customer accounts, and aligned customers to contracts to maximize savings. For 2013; 128% PPO for Gardasil HPV vaccine, 12% growth for Zostavax zoster vaccine, 98% PPO (113% growth) for Pneumovax 23 pneumococcal vaccine, and 118% PPO for Rotateq rotavirus vaccine.• Received 2Q 2013 OZ Award for enhanced account management.• Received 2014 Award of Excellence for activities within the Health One key account.• Received Director’s Club award for Top 30% of sales performance for Gardasil.

Managed vaccine promotion and sales to pediatricians, primary care physicians, OB/GYN providers, public health clinics, and hospitals. Promoted Singulair for pediatric asthma to pediatricians. Sucessfully prepared OB/GYN market for launch of Gardsil for HPV Prevention. Increased vaccine sales in 2005 from 76% PPO to 119%, and 2004 from 80% PPO to 109%. Achieved 79% market share for Recombivax HB in the hospital market in 2004. • District 16 Vice President's Club Award for 2004.

Led regional sales efforts with public health, FQHCs, private VFC offices, and military. Successfully generated growth of public sector vaccine purchases. 2003 Sales Performance: Pneumovax, 261% PPO; Comvax, 133% PPO; Pedvax Hib, 212% PPO; VAQTA 126% PPO. • VIPeer Award for team work and leadership in 2001.

Promoted vaccines to public sector customers such as the Texas Department of Health, city and county health departments, and military bases. Promoted Singulair for pediatric asthma to private practice pediatricians. • VIPeer Award for team work and leadership in 2000.